Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aadi Bioscience (AADI – Research Report) and Bioventus (BVS – Research Report).
Aadi Bioscience (AADI)
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Aadi Bioscience, with a price target of $45.00. The company’s shares closed last Tuesday at $7.14, close to its 52-week low of $6.80.
According to TipRanks.com, Burns has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aadi Bioscience with a $36.25 average price target, representing a 423.8% upside. In a report issued on May 11, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $33.00 price target.
See today’s best-performing stocks on TipRanks >>
Bioventus (BVS)
In a report released today, Alexander Nowak from Craig-Hallum maintained a Hold rating on Bioventus, with a price target of $2.00. The company’s shares closed last Tuesday at $1.20, close to its 52-week low of $0.80.
According to TipRanks.com, Nowak has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Bioventus is a Hold with an average price target of $2.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AADI:
- Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial
- Is AADI a Buy, Before Earnings?
- Aadi Bioscience price target lowered to $45 from $48 at H.C. Wainwright
- Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update
- Aadi Bioscience reports Q4 EPS (52c), consensus (71c)
